Merck: Navigating Patent Cliff and Growth Prospects
Merck faces the challenge of expiring patents while pushing a robust pipeline and disciplined capital moves. This gui...
Understand the typical fees associated with dividend ETFs, including fund-level and transaction costs, so you can compare options and keep more of your returns.
11,066 articlesMerck faces the challenge of expiring patents while pushing a robust pipeline and disciplined capital moves. This gui...
In May, Marvell Technology delivered more than a beat on sentiment, aided by AI infrastructure demand and a strategic...
As Treasury yields rise, a clearer message is emerging for investors: borrowing costs are up, risk appetites tilt, an...
Singapore's companies dominate the Southeast Asia 500 by revenue, capturing roughly a third of the region's total. Th...
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
History offers a steady compass for investors facing 2026. This article breaks down what history reveals about market...
AI progress rests on more than cool gadgets. This infrastructure stock more sits at the backbone of data centers, clo...
Sirius XM stunned investors with a near-50% rise in the first half of 2026. This analysis breaks down the catalysts, ...
A blockbuster TSMC update is reshaping the AI chip market. Here are three stocks I’m buying after Taiwan’s announceme...
When KD shares surged mid-morning, traders asked if the move reflected real earnings momentum or relief from a scare....
Stepan (SCL) investors are focused on 2025 earnings drivers, margins, and cash flow. This guide breaks down the key c...
Vistance (VISN) reports for 2025 show meaningful progress in revenue and margins, but the real story is how the compa...